ALK and non-small cell lung carcinoma: A scenario based on the ALK+ population as proxy for ROS1+ NSCLC patients showed a slightly more favorable cost-effectiveness profile for crizotinib, as does a scenario assuming maintenance outcomes are captured in the ROS1+ chemotherapy data.